Changeflow GovPing Healthcare & Life Sciences Phase 3 RCT of Electroacupuncture at Jing-Well ...
Routine Notice Added Final

Phase 3 RCT of Electroacupuncture at Jing-Well Points for Chronic Disorder of Consciousness

Favicon for changeflow.com ClinicalTrials.gov Studies
Published
Detected
Email

Summary

NIH registered a Phase 3 randomized controlled trial (NCT07551076) studying electroacupuncture at Twelve Hand Jing-Well points for chronic disorders of consciousness (DOC). The trial will enroll patients with DOC lasting more than 28 days following severe central nervous system injury, a condition affecting 300,000–800,000 patients worldwide with 29%–50% annual mortality. The study uses electrostimulation as the sole intervention and will employ multimodal assessment to evaluate efficacy, mechanisms, and suitable patient populations.

“Acupuncture, such as the Xingnao Kaiqiao method, induces arousal by improving cerebral blood flow and activating neural networks.”

NIH , verbatim from source
Published by NIH on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

ClinicalTrials.gov is the NIH-run registry of every clinical trial conducted in the United States, plus most international trials sponsored by US-based companies or institutions. By federal law, sponsors must register Phase 2 through Phase 4 studies before enrolling patients and post results within a year of completion. This feed tracks every new trial registration and study update, around 700 a month: drug interventions, device studies, behavioral protocols, observational research. Watch this if you scout drug candidates moving into mid or late-stage development, monitor competitor pipelines, or follow rare disease research where new trials signal patient hope. GovPing parses sponsor, phase, intervention, and target indication on each entry.

What changed

A new Phase 3 randomized controlled trial registration for electroacupuncture at Jing-Well points has been added to ClinicalTrials.gov. The study targets chronic disorders of consciousness lasting more than 28 days following severe central nervous system injury, a condition with limited treatment options and poor outcomes. Researchers and healthcare providers conducting or referring patients to similar studies should note this trial's emphasis on standardized multimodal assessment and large-sample evidence generation. No compliance obligations arise from this registry entry, but clinical teams managing DOC patients may wish to monitor enrollment eligibility criteria for potential referral pathways.

This registry entry does not impose regulatory obligations on healthcare providers or institutions. However, the trial's focus on a patient population with high mortality (29%–50% annually) and its investigation of electroacupuncture—already used in preliminary studies showing improved consciousness outcomes—may signal growing clinical interest in non-pharmacological neuromodulation approaches for severe brain injury. Institutions with traumatic brain injury programs should review whether their current DOC management protocols align with emerging evidence from trials like this one.

Archived snapshot

Apr 24, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← ClinicalTrials.gov Studies

Electroacupuncture at Jing-Well Points for Chronic Disorders of Consciousness: A Randomized Controlled Study With Multimodal Assessment

Phase 3 NCT07551076 Kind: PHASE3 Apr 24, 2026

Abstract

Disorder of consciousness (DOC) is a common complication of severe central nervous system injury. It is defined as prolonged DOC when lasting more than 28 days. About 300,000-800,000 patients are affected worldwide, with an annual mortality rate of 29%-50%, causing a heavy social and family burden.

Although progress has been made in pathophysiology, clinical outcomes remain unsatisfactory, and arousal treatment for DOC is still challenging. Internationally recommended therapies, such as neurotrophic drugs, hyperbaric oxygen and invasive neuromodulation, have side effects or uncertain efficacy.

In traditional Chinese medicine, post-TBI DOC is classified as "shen hun" (mental clouding). Bloodletting at Jing-Well points promotes arousal by regulating qi and blood and unblocking collaterals. Preliminary studies showed it may improve consciousness in DOC patients, but with small samples and short observation periods.

Acupuncture, such as the Xingnao Kaiqiao method, induces arousal by improving cerebral blood flow and activating neural networks. Our team proposed the "Jing-Well point-brain correlation" hypothesis and found that electrostimulation at Jing-Well points improves cognitive function, but lacks standardized assessment and large-sample evidence.

Further research is needed to confirm its efficacy, mechanisms and suitable populations to provide high-quality evidence-based support.

Conditions: Disorder of Consciousness

Interventions: Electrostimulation at the Twelve Hand Jing-Well Points

View original document →

Get daily alerts for ClinicalTrials.gov Studies

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from NIH.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
NIH
Published
April 24th, 2026
Instrument
Notice
Branch
Executive
Legal weight
Non-binding
Stage
Final
Change scope
Minor

Who this affects

Applies to
Clinical investigators Healthcare providers
Industry sector
6211 Healthcare Providers
Activity scope
Clinical trial registration Electroacupuncture research Neuromodulation therapy
Geographic scope
United States US

Taxonomy

Primary area
Healthcare
Operational domain
Regulatory Affairs
Topics
Pharmaceuticals Medical Devices

Get alerts for this source

We'll email you when ClinicalTrials.gov Studies publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!